Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JMAC Maxpro Capital Acquisition	$6.06 -4.6%	$6.14	$7.50 ▼ $19.22	$81.37M	0.01	74,040 shs	4,030 shs
MIRA MIRA Pharmaceuticals	$1.22 -0.8%	$1.20	$0.51 ▼ $5.01	$20.81M	1.96	2.20 million shs	84,335 shs
OCX OncoCyte	$3.18 +16.3%	$2.99	$1.92 ▼ $4.75	$90.80M	0.97	59,206 shs	100,514 shs
ZURA Zura Bio	$1.13 +1.8%	$1.21	$0.97 ▼ $5.07	$75.90M	-0.12	439,600 shs	536,762 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JMAC Maxpro Capital Acquisition	0.00%	-11.09%	+13.80%	-38.79%	+2,848.91%
MIRA MIRA Pharmaceuticals	-0.81%	+0.83%	+0.83%	-4.69%	+71.83%
OCX OncoCyte	0.00%	+19.81%	+3.42%	-6.62%	+18.03%
ZURA Zura Bio	+1.80%	-5.83%	+9.71%	-18.71%	-66.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	2.3823 of 5 stars	3.7	5.0	0.0	0.0	0.6	0.0	0.6
OCX OncoCyte	1.8905 of 5 stars	3.4	4.0	0.0	0.0	0.0	0.8	0.6
ZURA Zura Bio	2.5314 of 5 stars	3.6	1.0	0.0	0.0	2.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	3.33	Buy	$14.00	1,047.54% Upside
OCX OncoCyte	2.75	Moderate Buy	$6.06	90.94% Upside
ZURA Zura Bio	3.13	Buy	$14.33	1,168.44% Upside

Current Analyst Ratings Breakdown

Latest MIRA, JMAC, ZURA, and OCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	OCX OncoCyte	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/21/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $8.00
5/13/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/8/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/28/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A
OCX OncoCyte	$3.84M	23.63	N/A	N/A	($0.70) per share	-4.54
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.51	N/A	N/A	N/A	N/A	-341.08%	-272.93%	8/12/2025 (Estimated)
OCX OncoCyte	-$60.66M	-$3.53	N/A	N/A	N/A	-1,516.06%	-215.59%	-27.23%	8/6/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-42.84%	-35.22%	8/12/2025 (Estimated)

Latest MIRA, JMAC, ZURA, and OCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRA MIRA Pharmaceuticals	-$0.15	-$0.11	+$0.04	-$0.11	N/A	N/A
5/12/2025	Q1 2025	OCX OncoCyte	-$0.24	-$0.26	-$0.02	-$0.26	$0.13 million	$2.14 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
3/28/2025	Q4 2024	MIRA MIRA Pharmaceuticals	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million
3/24/2025	Q4 2024	OCX OncoCyte	-$0.40	$0.48	+$0.88	-$1.93	$0.16 million	$1.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86
OCX OncoCyte	0.20	3.74	3.70
ZURA Zura Bio	N/A	8.14	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JMAC Maxpro Capital Acquisition	73.18%
MIRA MIRA Pharmaceuticals	35.16%
OCX OncoCyte	55.35%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
JMAC Maxpro Capital Acquisition	19.27%
MIRA MIRA Pharmaceuticals	6.65%
OCX OncoCyte	2.05%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	16.92 million	15.80 million	Not Optionable
OCX OncoCyte	120	28.60 million	28.01 million	No Data
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

MIRA, JMAC, ZURA, and OCX Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Average PT from Analysts

June 21 at 1:35 AM | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Buy" by Analysts

June 18 at 3:38 AM | marketbeat.com

Cantor Fitzgerald Weighs in on Zura Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)

June 3, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by Brokerages

May 26, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

HC Wainwright Issues Positive Estimate for Zura Bio Earnings

May 23, 2025 | marketbeat.com

Q1 Earnings Estimate for Zura Bio Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA, JMAC, ZURA, and OCX Company Descriptions

Maxpro Capital Acquisition NASDAQ:JMAC

$6.06 -0.30 (-4.64%)

As of 06/18/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.22 -0.01 (-0.81%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.22 0.00 (-0.41%)

As of 06/20/2025 07:46 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

OncoCyte NASDAQ:OCX

$3.18 +0.45 (+16.30%)

Closing price 06/17/2025 07:21 PM Eastern

Extended Trading

$3.18 0.00 (0.00%)

As of 06/17/2025 07:21 PM Eastern

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Zura Bio NASDAQ:ZURA

$1.13 +0.02 (+1.80%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.19 +0.06 (+5.66%)

As of 06/20/2025 07:38 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time